[Intervention efficacy of lamivudine on liver dysfunction in patients undergoing anti-tuberculosis treatment for pulmonary tuberculosis complicated with  chronic hepatitis B: a Meta-analysis].
OBJECTIVE
To analyze the intervention efficacy of lamivudine on liver dysfunction in patients undergoing anti-tuberculosis treatment for pulmonary tuberculosis complicated with chronic hepatitis B.


METHODS
Corresponding data were retrieved from PubMed, Web of Science, Embase, the Cochrane Library, Chinese Biomedical Literature (CBM), VIP, China National Knowledge Infrastructure (CNKI) and Wanfang Database with randomly controlled trials regarding the chronic hepatitis B and tuberculosis by lamivudine. Statistical analysis was performed by Meta-analysis using Stata11.0.


RESULTS
Fifteen randomly controlled trials including 967 chronic hepatitis B and tuberculosis cases met the inclusion criteria (564 cases in observation group and 403 cases in control group). Meta-analysis showed that the values of ALT, AST, TBIL and HBV-DNA load in the observation group were lower than those in the control group. The values of standardized mean difference (95% CI) were -2.58 (-3.55, -1.60), -2.43 (-3.33, -1.54), -1.56 (-2.18, -0.94) and -6.91 (-8.90, -4.92), while the combined effect of OR values for liver damage was 0.11 (0.06, 0.19). There were significant differences in the combined effect of each value between the two groups (P<0.05).


CONCLUSIONS
The intervention efficacy of lamivudine on liver dysfunction in patients undergoing anti-tuberculosis treatment for pulmonary tuberculosis complicated with chronic hepatitis B patients was good, which can reduce hepatitis B viral load levels.
Department of Epidemiology and Health Statistics, School of Public Health, Central South University, Changsha 410078, China.
Shisheng
S
Hui
Department of Epidemiology and Health Statistics, School of Public Health, Central South University, Changsha 410078, China.
Lizhang
L
Chen
Department of Epidemiology and Health Statistics, School of Public Health, Central South University, Changsha 410078, China.
Zhanzhan
Z
Li
D000995:Antitubercular Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D002681:China; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy; D019562:Viral Load
D000995:Antitubercular Agents; D000998:Antiviral Agents; D019259:Lamivudine